Acute Assessment of the Aria CV System in Patients With WHO Groups 2 and 3 Pulmonary Hypertension

Acute Feasibility Study Assessing Safety and Performance of Aria CV Acute PH System in Patients With WHO Group 2 and 3 Pulmonary Hypertension

This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.

Study Overview

• Status: Completed
• Conditions: Pulmonary Hypertension
• Intervention / Treatment: Device: Aria CV Acute PH System

Detailed Description

This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.

The planned enrollment is a maximum enrollment of 40 patients to ensure up to 10 "Device Deployed" subjects in each arm at one site.

The duration of study participation for each subject is expected to be approximately 60 days.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Rachel Currie, MPH; Phone Number: 651-200-4892; Email: rcurrie@ariacv.com

Study Locations

• Austria
  • Vienna, Austria
    • Medical University of Vienna

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria for WHO Group 2

1. 18 years or older
2. Symptomatic WHO Functional Class (FC) III

3. Based on preexisting echocardiography within the past 6 months, evidence of right heart dysfunction: RV ejection fraction (RVEF) < 45% by visual estimate, and at least one of the following:

   1. Tricuspid Annulus Plane Systolic Excursion (TAPSE) ≤16 mm
   2. RV Fractional area change <35%
   3. RVs' velocity < 10 cm/s
   4. RV free wall strain <18%
   5. RVEF < 35% by visual estimate
4. MPA diameter > 32mm and length >70 mm as determined by preexisting fluoroscopy, echocardiography, computerized tomography, or magnetic resonance imaging within the past 6 months.
5. Elevated pulmonary arterial pressure based on preexisting resting RHC within the past 6 months: Mean PAP (mPAP) > 30 mmHg
6. Intra-procedural confirmation of elevated pulmonary arterial pressure based on resting RHC: mPAP > 30 mmHg
7. Patient is willing and able to provide informed consent.
8. Previous diagnosis of left heart dysfunction.

9. Intra-procedural confirmation of WHO Group 2 diagnosis based on resting RHC:

   1. PAWP: >15 and ≤30 mmHg, and
   2. Combined post- and pre-capillary pulmonary hypertension (CpcPH), defined as PVR > 3 WU

Exclusion Criteria for WHO Group 2

1. Anatomy not suitable for RHC

2. Anatomy not suitable for placement of Aria CV Acute Device:

   1. Contraindication to 16 Fr femoral vein access
   2. Body habitus that would preclude safe placement of any components of Aria CV Acute Device
3. Any previous tricuspid valvular surgery, percutaneous valve repair, or presence of prosthetic cardiac device such as pacemaker or defibrillator leads, or vena cava filter that in the opinion of the investigator may interfere with investigational device placement or performance
4. Uncontrolled atrial fibrillation
5. Sustained tachyarrhythmia (heart rate >110/min) at time of index procedure

6. Right heart valve regurgitation:

   1. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation
   2. Severe (Grade 4) tricuspid valve regurgitation

7. Patient with any of the following medical history or comorbidities:

   1. History of unprovoked Pulmonary Embolism or CTEPH
   2. Currently on dialysis
   3. Current or recent (<6 months prior to planned index procedure) endocarditis
   4. Clinically significant patent foramen ovale or other inter-atrial or inter-ventricular shunt
   5. Current active systemic infection requiring antibiotic therapy
8. As determined by the physician the subject is medically unstable and/or represents an unreasonable procedural risk.

9. Hypersensitivity or contraindication to

   1. Required medications (e.g. contrast agents, heparin) which cannot be adequately managed, or
   2. Materials in investigational device including polyurethane, silicone, nickel, and titanium
10. Pregnant or lactating woman
11. Currently participating in other investigational drug or device trials that may interfere with the outcome of this study
12. Diagnosis of WHO Groups 1, 3, 4 or 5 PH
13. Previous diagnosis of idiopathic hypertrophic subaortic stenosis (IHSS, also known as hypertrophic obstructive cardiomyopathy-HOCM)
14. Untreated aortic or mitral stenosis

Inclusion Criteria for WHO Group 3

1. 18 years or older
2. Symptomatic WHO Functional Class (FC) III

3. Based on preexisting echocardiography within the past 6 months, evidence of right heart dysfunction: RV ejection fraction (RVEF) < 45% by visual estimate, and at least one of the following:

   1. Tricuspid Annulus Plane Systolic Excursion (TAPSE) ≤16 mm
   2. RV Fractional area change <35%
   3. RVs' velocity < 10 cm/s
   4. RV free wall strain <18%
   5. RVEF < 35% by visual estimate
4. MPA diameter > 32mm and length >70 mm as determined by preexisting fluoroscopy, echocardiography, computerized tomography, or magnetic resonance imaging within the past 6 months
5. Elevated pulmonary arterial pressure based on preexisting resting RHC within the past 6 months: Mean PAP (mPAP) > 30 mmHg
6. Intra-procedural confirmation of elevated pulmonary arterial pressure based on resting RHC: mPAP > 30 mmHg
7. Patient is willing and able to provide informed consent
8. Previous diagnosis of chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF) or combined emphysema with fibrosis

9. Intra-procedural confirmation of WHO Group 3 diagnosis based on resting RHC:

   1. PAWP≤ 15 mmHg, and
   2. PVR > 4 WU

Exclusion Criteria for WHO Group 3

1. Anatomy not suitable for RHC

2. Anatomy not suitable for placement of Aria CV Acute Device:

   1. Contraindication to 16 Fr femoral vein access
   2. Body habitus that would preclude safe placement of any components of Aria CV Acute device
3. Any previous tricuspid valvular surgery, percutaneous valve repair, or presence of prosthetic cardiac device such as pacemaker or defibrillator leads, or vena cava filter that in the opinion of the investigator may interfere with investigational device placement or performance
4. Uncontrolled atrial fibrillation
5. Sustained tachyarrhythmia (heart rate >110/min) at time of index procedure

6. Right heart valve regurgitation:

   1. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation
   2. Severe (Grade 4) tricuspid valve regurgitation

7. Patient with any of the following medical history or comorbidities:

   1. History of unprovoked Pulmonary Embolism or CTEPH
   2. Currently on dialysis
   3. Current or recent (<6 months prior to planned index procedure) endocarditis
   4. Clinically significant shunt such as patent foramen ovale, inter-atrial or inter-ventricular shunt, or other.
   5. Current active systemic infection requiring antibiotic therapy
8. As determined by the physician the subject is medically unstable and/or represents an unreasonable procedural risk.

9. Hypersensitivity or contraindication to

   1. Required medications (e.g. contrast agents, warfarin, heparin) which cannot be adequately managed, or
   2. Materials in investigational device including polyurethane, silicone, nickel, and titanium.
10. Pregnant or lactating woman
11. Currently participating in other investigational drug or device trials that may interfere with the outcome of this study
12. Diagnosis of WHO Groups 1, 2, 4 or 5 PH

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: WHO Group 2	Device: Aria CV Acute PH System; The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.
Experimental: WHO Group 3	Device: Aria CV Acute PH System; The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Safety Endpoint	Incidence of investigational device-related serious adverse events (SAEs) through 30 days post-index procedure, based on Clinical Events Committee assessment.	30 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Safety Endpoint	All reported adverse events occurring during the study will be summarized by the CEC for seriousness and relatedness based on site-reported data.	30 Days

Collaborators and Investigators

• Sponsor: Aria CV, Inc
• Investigators: Principal Investigator: Irene M Lang, MD, Medical University of Vienna

Study record dates

Study Major Dates

• Study Start (Actual): July 12, 2021
• Primary Completion (Actual): December 30, 2021
• Study Completion (Actual): January 6, 2022

Study Registration Dates

• First Submitted: July 26, 2021
• First Submitted That Met QC Criteria: August 3, 2021
• First Posted (Actual): August 12, 2021

Study Record Updates

• Last Update Posted (Actual): March 20, 2024
• Last Update Submitted That Met QC Criteria: March 18, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension; Hypertension, Pulmonary
• Other Study ID Numbers: ARIACV202101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No